Haematologica, Vol 92, Issue 5, 686-689 doi:10.3324/haematol.10879
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pulini, S.
Right arrow Articles by Leoni, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pulini, S.
Right arrow Articles by Leoni, P.

Malignant Lymphomas

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

Stefano Pulini, Serena Rupoli, Gaia Goteri, Nicola Pimpinelli, Renato Alterini, Angela Tassetti, Anna Rita Scortechini, Massimo Offidani, Simonetta Mulattieri, Andrea Stronati, Giuliano Brandozzi, Alfredo Giacchetti, Giorgio Mozzicafreddo, Giuseppe Ricotti, Giorgio Filosa, Alberta Bettacchi, Marco Simonacci, Nicolino Novelli, Pietro Leoni

From the Clinic of Hematology, Polytechnic University of the Marche Medical School, Ospedali Riuniti, Ancona, Italy (SP, SR, PL, AT, ARS, MO, SM, AS); Institute of Pathology, Department of Neurosciences, Polytechnic University of the Marche Medical School, Ospedali Riuniti, Ancona, Italy (GG); Department of Dermatological Sciences, University of Florence Medical School, Florence, Italy (NP); Department of Hematology, University of Florence Medical School, Florence, Italy (RA); Clinic of Dermatology, Polytechnic University of the Marche Medical School, Ospedali Riuniti, Ancona, Italy (GB) Division of Dermatology, I.N.R.C.A., Ancona, Italy (AG, GM, GR); Division of Dermatology, Jesi, Italy (GF); Division of Dermatology, Macerata, Italy (AB, MS); Dermatology, Grottammare, Italy (NN)

Correspondence: Stefano Pulini, MD, Clinic of Hematology, Polytechnic University of the Marche, Medical School, Ospedali Riuniti Umberto I, G.M. Lancisi-G. Salesi, via Conca 71, 60020 Ancona, Italy. E-mail: stpulini{at}bigfoot.com

Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I–IIA and IIB–IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.

Key words: pegylated liposomal doxorubicin, primary cutaneous T-cell lymphomas, mycosis fungoides, Sézary syndrome.




This article has been cited by other articles:


Home page
 BloodHome page
H. M. Prince, S. Whittaker, and R. T. Hoppe
How I treat mycosis fungoides and Sezary syndrome
Blood, November 12, 2009; 114(20): 4337 - 4353.
[Abstract] [Full Text] [PDF]